Compare TG Therapeutics Inc (TGTX) vs Verizon Communications Inc (VZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Verizon Communications Inc — how do they compare? TG Therapeutics Inc trades at $55.24 (market cap $8.16B), while Verizon Communications Inc trades at $41.81 (market cap $192.57B). The key difference: Verizon Communications Inc is far larger — about 23.6× TG Therapeutics Inc's market cap, and Verizon Communications Inc pays a 6.11% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and Verizon Communications Inc for 109 Days on average.
| TGTX | VZ | |
|---|---|---|
Market Cap | $8.16B | $192.57B |
Volume | 1,735,121 | 20,940,094 |
Sector | Health | Media |
52-Week High | $59.06 | $51.45 |
52-Week Low | $26.94 | $38.40 |
Typical Hold Time | 16 Days | 109 Days |
Enterprise Value | $8.37B | $379.28B |
Dividend Yield | — | 6.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Verizon (VZ) trades at $41.115, down 10.17% over the past day, reflecting recent market pressure. The stock shows a bearish technical signal with key support at $45. Fundamentally, VZ maintains solid profitability with a 59.26% gross margin and has beaten earnings estimates in recent quarters. The company generates strong operating cash flow of $37.14 billion (2025) and offers a consistent dividend, with recent payouts of $0.71 per share. Analyst consensus is a 'Hold' with a $48.17 price target, indicating potential upside from current levels.
The outlook for VZ hinges on execution in the competitive telecom sector. Opportunities include stable cash flow supporting dividends and joint ventures expanding coverage. Risks involve high debt levels, with total debt at $144.01 billion, and pressure from rivals like T-Mobile. Earnings on October 26, 2026, will be critical for confirming growth trends amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Verizon Communications Inc
Verizon Communications Inc. is an integrated telecommunications company that provides wire line voice and data services, wireless services, Internet services, and published directory information. The Company also provides network services for the federal government including business phone lines, data services, telecommunications equipment, and payphones.
Read more on VZ →
